Publication of prospectus regarding Enzymatica’s rights issue
Regulatory information
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW.
The prospectus (the “Prospectus”) for Enzymatica AB’s rights issue of around SEK 130 million (the “Rights issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).
The prospectus (the “Prospectus”) for Enzymatica AB’s rights issue of around SEK 130 million (the “Rights issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).
The Prospectus can be obtained from Enzymatica and Hagberg & Aneborn Fondkommission AB (“Hagberg & Aneborn”) and is available on Enzymatica’s website (www.enzymatica.com) and on Hagberg & Aneborn’s website (www.hagberganeborn.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on Enzymatica’s and Hagberg & Aneborn’s websites from August 28, 2024.
Timetable for the Rights issue
| August 22, 2024 | Last day of trading in the share including subscription rights |
| August 23, 2024 | First day of trading in the share excluding subscription rights |
| August 26, 2024 | Record date for participation in the Rights issue |
| August 28 – September 6, 2024 | Trading in subscription rights |
| August 28 – September 13, 2024 | Subscription period |
| September 12, 2024 | Estimated date of announcement of the outcome of the Rights issue |
Hagberg & Aneborn is Enzymatica’s financial adviser and Setterwalls Advokatbyrå is Enzymatica’s legal adviser in connection with the Rights issue.